%0杂志文章%A Distler, Oliver %A刺客，Shervin %A cotin, Vincent %A Cutolo, Maurizio %A Danoff, Sonye K. %A Denton, Christopher P. %A Distler, Jörg H.W. %A Hoffmann-Vold, Anna-Maria %A Johnson, Sindhu R. %A Müller Ladner, Ulf %A Smith, Vanessa %A Volkmann, Elizabeth R. %A Maher，Toby M. %T预测间质性肺疾病的系统性硬化症患者进展的指标%D 2020 %R 10.1103 /13993003.02026-2019 %J欧洲呼吸杂志%P 1902026 %V 55% N 5% X系统性自身免疫性疾病是一种影响包括肺在内的多器官系统的系统性自身免疫疾病。间质性肺病(ILD)是SSc患者死亡的主要原因。目前尚无有效的生物标志物预测SSc-ILD的发生，尽管抗拓扑异构酶I的自身抗体和一些炎症标志物是需要进一步评估的候选生物标志物。胸部听诊、气短和肺功能检测是重要的诊断工具，但对早期肺间质性肺病缺乏敏感性。因此，基线筛查高分辨率计算机断层扫描(HRCT)是必要的，以确认SSc-ILD诊断。一旦诊断为SSc-ILD，患者的临床病程变化多端且难以预测，尽管某些患者特征和生物标志物与疾病进展相关。监测SSc-ILD患者疾病进展的迹象是重要的，尽管对于使用何种诊断工具或监测的频率没有共识。在这篇文章中，我们回顾了用于定义和预测SSc-ILD疾病进展的方法。SSc-ILD疾病进展尚无有效定义，但我们认为，强迫肺活量(FVC)从基线下降≥10%，或FVC下降5-9%，与一氧化碳肺弥散能力下降≥15%相关，均表示进展。 An increase in the radiographic extent of ILD on HRCT imaging would also signify progression. A time period of 1–2 years is generally used for this definition, but a decline over a longer time period may also reflect clinically relevant disease progression.Lung function tests and chest imaging help predict who has SSc-associated ILD and whether it will progress. In the absence of standardised methods for doctors, we recommend a strategy that combines both lung function tests and chest imaging. http://bit.ly/2uK9ZD2 %U //www.qdcxjkg.com/content/erj/55/5/1902026.full.pdf